Latest Diabetes News
Advisory Committee on Immunization Practices Votes to Recommend Vaccine for Patients Under 60
By Daniel J. DeNoon
WebMD Health News
Reviewed by Laura J. Martin, MD
By a 12-2 vote, the ACIP strongly recommended the hepatitis B vaccine for diabetes patients under age 60 who have not been fully vaccinated. It also urged hepatitis vaccination of some older diabetes patients.
Up to age 60, people with diabetes have twice the risk of hepatitis B as those without diabetes. Yet only 17% of those living with diabetes (and 26% of those without diabetes) have been fully vaccinated against hepatitis B.
Lifetime Protection Against Hepatitis B
The ACIP balked at making a stronger recommendation for older diabetes patients. Committee members were strongly influenced by the cost of vaccinating all over-60 people with diabetes. Also a factor in their decision is data showing that the vaccine is less likely to be effective in those who are frail and elderly.
The hepatitis vaccine is most effective in young adults. If they haven't already been vaccinated, people should get the hepatitis B vaccine as soon as they learn of their diabetes diagnosis, the ACIP advises. The three- or four-dose series offers protection that usually lasts a lifetime.
The hepatitis B virus infects the liver. While some people fight off the infection, others don't. Some 1.25 million Americans have long-lasting (chronic) hepatitis B infection. In the U.S., hepatitis B kills 3,000 to 5,000 people a year.
The ACIP is made up of independent experts who advise the CDC and FDA on vaccination policy. The committee's recommendations form the basis of the U.S. immunization schedules.